Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
McGill University Health Centre/Research Institute of the McGill University Health Centre
McGill University Health Centre/Research Institute of the McGill University Health Centre
BeOne Medicines
Bristol-Myers Squibb
Swiss Cancer Institute
Janssen Research & Development, LLC
AstraZeneca
Seagen Inc.
M.D. Anderson Cancer Center
Gustave Roussy, Cancer Campus, Grand Paris
H. Lee Moffitt Cancer Center and Research Institute
Arcus Biosciences, Inc.
AstraZeneca
Shanghai Pulmonary Hospital, Shanghai, China
University of Iowa
Wake Forest University Health Sciences
Gilead Sciences
Hunan Province Tumor Hospital
Hoffmann-La Roche
AstraZeneca
Hackensack Meridian Health
Merck Sharp & Dohme LLC
Massachusetts General Hospital
Gilead Sciences
Hoffmann-La Roche
Intergroupe Francophone de Cancerologie Thoracique
ETOP IBCSG Partners Foundation
BeOne Medicines
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
TJ Biopharma Co., Ltd.
Klus Pharma Inc.
Tianjin Medical University Cancer Institute and Hospital
University of Pittsburgh
Dana-Farber Cancer Institute
Beijing Cancer Prevention & Treatment Society
Abramson Cancer Center at Penn Medicine
Fundación GECP
Sun Yat-sen University
University Health Network, Toronto
Mario Negri Institute for Pharmacological Research
Università Vita-Salute San Raffaele
CSPC Megalith Biopharmaceutical Co.,Ltd.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Shanghai Hengrui Pharmaceutical Co., Ltd.
Mayo Clinic
Lantern Pharma Inc.
Fundación GECP
Fundación GECP
Intergroupe Francophone de Cancerologie Thoracique
Washington University School of Medicine